Biosimilar Legal Landscape: Lessons From 2017
Executive Summary
In several firsts last year, US Supreme Court ruled on BPCIA, Amgen won a damages award in infringement litigation, and Amgen and Mylan inked deals clearing way for future launch of Humira and Herceptin biosimilars. Chart includes status of 15 cases and questions teed up for courts to tackle in 2018.
You may also be interested in...
Tentative Biosimilar Approvals Under Consideration By FDA
Concept could help sponsors who reach approvability but must wait several years before reference product exclusivity expires.
Tentative Biosimilar Approvals A Consideration for the US FDA
Concept could help sponsors who reach approvability but must wait several years before reference product exclusivity expires.
The Future Of US Biosimilars Litigation: Method-Of-Use Patents And ‘Dance’ Obligations
Expect plenty of litigation over what constitutes infringement of a method-of-use patent even when the protected indication is not found on a biosimilar’s labeling, a panel of legal experts said at the recent BIO meeting; another area of unsettled law is the extent to which a biosimilar sponsor has satisfied the information-exchange provisions of the BPCIA ‘patent dance.’